. 2021 Apr 15;11:8288. doi: 10.1038/s41598-021-87417-2

Table 2.

Potency (pEC₅₀) and maximal effect (E_max) estimates for agonists activating D₂R regulatory pathways.

Agonist	pSer³¹⁷/pThr³¹⁸		GRK2		β-arr2
Agonist	pEC₅₀	E_max	pEC₅₀	E_max	pEC₅₀	E_max
Dopamine	6.40 ± 0.45	100	6.84 ± 0.04	100.0	7.13 ± 0.05	100.0
Apomorphine	7.42 ± 0.10	84 ± 3	7.68 ± 0.09	56.2 ± 2.1	7.85 ± 0.05	81.2 ± 1.7
Aripiprazole	ND	ND	ND	ND	6.23 ± 0.25	10.3 ± 1.5
Bromocriptine	6.84 ± 0.25	57 ± 2	7.18 ± 0.06	38.7 ± 1.1	7.10 ± 0.05	66.3 ± 1.3
Cabergoline	7.38 ± 0.25	61 ± 2	8.36 ± 0.07	54.4 ± 1.4	8.29 ± 0.04	83.7 ± 1.2
MLS1547	ND	ND	5.20 ± 0.27	26.1 ± 7.8	5.59 ± 0.13	33.6 ± 3.8
Pergolide	7.73 ± 0.46	79 ± 2	7.67 ± 0.06	50.8 ± 1.2	7.83 ± 0.04	76.7 ± 1.3
Quinpirole	7.06 ± 0.17	83 ± 1	7.13 ± 0.04	62.9 ± 1.2	7.38 ± 0.03	88.6 ± 1.2
Ropinirole	6.77 ± 0.22	77 ± 2	6.72 ± 0.07	59.1 ± 2.0	6.99 ± 0.04	76.8 ± 1.4
Roxindole	7.52 ± 0.09	10 ± 1	8.73 ± 0.15	24.3 ± 1.3	8.83 ± 0.07	41.0 ± 1.0
Terguride	ND	ND	8.10 ± 0.24	7.4 ± 0.7	8.33 ± 0.09	18.9 ± 0.6
UNC9994	ND	ND	5.45 ± 0.31	13.3 ± 3.8	5.63 ± 0.18	23.0 ± 3.3

Concentration–response curves from Figs. 3 and 4 were analyzed using a three-parameter fit (Eq. 1). Values represent the mean ± SEM. ND Not determined: unable to be determined due to insufficient response to allow accurate fitting of the model.